AAM, Doc told me once last year when I had hit my first
AAM, Doc told me once last year when I had hit my first share goal I would be a wealthy man. He knew then what was ahead. I talked with him last week and he said he has been working hard and was very tired, but he does not slow down. I think he has about come to the point he is simply waiting on the SEC, but he did not tell me that. He will not share insider information, I can assure you of that. He does not say ask for pennies-get pennies-ask for dollars, get dollars for nothing. It really is pathetic what some are saying about Doc-they just do not know. UNVC Conglomerate will be the Berkshire Hathaway of the cannabis sector.And he certainly is not doing all this hard work for the money-that I know. His goals are to help those in need and make shareholders wealthy. I have been in dozens of penny stocks as have most of you-was always dilution or mafia financing issues or R/S or something. Not here. I will not make any price predictions, but it will surpass any figure you had in mind when we all bought in. We really need to have a plan for our shares as we will soon be looking at mega-bucks, so be smart as Doc says. Those who are playing their evil games will probably make alot also, but those kind of people have a problem and will soon be broke. We are close I feel. GLTUA JB
9
Univec Conglomerate Inc (UNVC) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...
Continue Reading
Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....
Continue Reading
Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...
Continue Reading
AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...
Continue Reading
You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...
Continue Reading
Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...
Continue Reading
History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...
Continue Reading
Top 5 Most Recently Viewed Articles
Markets in Germany Prepare for Fluctuations As trading wrapped up on Wednesday, the German stock market exhibited a mixed bag of results. While certain sectors, such as Food & Beverages, Media, and Financial Services, reported gains, others faced setbacks. The Consumer & Cyclical, Construction, and Pharmaceuticals & Healthcare sectors saw declines, reflecting the market's...
Continue Reading
Teradyne's Q3 Earnings Exceed Expectations Teradyne Incorporated (NASDAQ: TER), a prominent player in automated test equipment, has released its third-quarter results, building a narrative of success and optimism. The company reported impressive sales figures of $737 million, with non-GAAP earnings per share (EPS) reaching $0.90, bolstered by a solid gross margin of...
Continue Reading
So-Young's Strategic Shift in ADS Ratio So-Young International Inc. (NASDAQ: SY), a leading aesthetic treatment platform, has recently announced plans to change the ratio of its American depositary shares (ADSs) to Class A ordinary shares. This strategic decision aims to refine its trading dynamics, enhancing value for its shareholders. Details of the ADS Ratio Change The...
Continue Reading
Contextual Overview of GitLab's Recent Investor Challenges In a rapidly evolving technological landscape, GitLab Inc. stands at a critical juncture as investors navigate its latest developments and challenges. Recent announcements regarding financial performance have sparked interest and concern among stakeholders. Understanding the implications of these changes is...
Continue Reading
15 Years of Innovation in Specialty Pharmacy Senderra Specialty Pharmacy has proudly reached a remarkable milestone—15 years of providing top-tier healthcare solutions in the specialty pharmacy sector. This anniversary embodies a journey marked by significant advancements and unwavering commitment to revolutionizing patient care. Transforming Patient Experiences Since...
Continue Reading
